Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
8.22B
Market cap8.22B
Price-Earnings ratio
-10.21
Price-Earnings ratio-10.21
Dividend yield
—
Dividend yield—
Average volume
2.12M
Average volume2.12M
High today
$68.71
High today$68.71
Low today
$65.43
Low today$65.43
Open price
$66.20
Open price$66.20
Volume
2.47M
Volume2.47M
52 Week high
$70.98
52 Week high$70.98
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $66.97, with a market capitalization of 8.22B. The stock trades at a price-to-earnings (P/E) ratio of -10.21.

On 2026-04-03, Cytokinetics(CYTK) stock traded between a low of $65.43 and a high of $68.71. Shares are currently priced at $66.97, which is +2.4% above the low and -2.5% below the high.

Cytokinetics(CYTK) shares are trading with a volume of 2.47M, against a daily average of 2.12M.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $70.98 at its peak.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $70.98 at its peak.

CYTK News

Simply Wall St 3h
A Look At Cytokinetics Valuation After MYQORZO FDA Approval And Aficamten Regulatory Updates

Advertisement Why Cytokinetics Stock Is Back in Focus Cytokinetics (CYTK) is drawing renewed attention after securing FDA approval for MYQORZO, with investors...

A Look At Cytokinetics Valuation After MYQORZO FDA Approval And Aficamten Regulatory Updates
TipRanks 17h
Cytokinetics price target raised to $95 from $87 at Barclays

Barclays analyst Emily Field raised the firm’s price target on Cytokinetics (CYTK) to $95 from $87 and keeps an Overweight rating on the shares. The firm says t...

TipRanks 1d
Top Executive’s Bold Stock Move Shakes Up Cytokinetics Investors

New insider activity at Cytokinetics ( (CYTK) ) has taken place on April 1, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharpe...

Analyst ratings

86%

of 21 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.
Pfizer
Plug Power
Moderna
Viking Therapeutics
Alibaba
AMD

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.